Perimeter Medical Imaging Ai Inc Stock Price, News & Analysis

Perimeter Medical Imaging AI, Inc. (TSX-V: PINK, OTC: PYNKF) announced its third-quarter financial results for 2022, highlighting key developments in its clinical trials and commercial placements. The company activated eight clinical trial sites for its B-Series OCT system with ImgAssist AI and received FDA approval for further expansion. Operating expenses rose to $5.94 million, while the net loss improved to $818,527 compared to $3.88 million in Q3 2021. Cash and cash equivalents stood at $43.2 million as of September 30, 2022.

CEO Jeremy Sobotta expressed optimism regarding ongoing trials and commercial adoption amid challenging conditions.

Perimeter Medical Imaging AI, Inc. (PYNKF) announced a successful commercial placement of its Perimeter S-Series OCT system at a second hospital within a major healthcare network in North Texas. This follows a prior placement within the same network and underscores Perimeter's strategy to expand its technology in integrated delivery systems. CEO Jeremy Sobotta highlighted positive feedback from end-users and stakeholders, indicating strong market validation for their advanced imaging tools aimed at transforming cancer surgery.

Perimeter Medical Imaging AI, Inc. (TSX-V: PINK, OTC: PYNKF) will announce its Q3 2022 financial results on November 15, 2022, after U.S. market close. A conference call is scheduled for the same day at 5:00 PM ET, featuring CEO Jeremy Sobotta and CFO Chris Scott. The call will be accessible via dial-in and webcast, with details available on the Company's website. Perimeter focuses on innovative imaging solutions for cancer surgery, aiming to enhance surgical outcomes.

Perimeter Medical Imaging AI, Inc. (PYNKF) announces the results of its 2022 annual and special meeting of shareholders held on October 27, 2022. Shareholders approved all matters, including the election of seven board members and a new omnibus equity incentive plan. The Omnibus Plan allows the issuance of options and units, capping at 12,834,531 common shares. Additionally, KPMG LLP was reappointed as the company’s auditor for the upcoming year. Perimeter focuses on innovative imaging tools to enhance cancer surgery, with promising products currently in evaluation.

Perimeter Medical Imaging AI (OTC:PYNKF) announced significant findings at the College of American Pathologists Annual Meeting 2022. Their research highlights the use of the Perimeter S-Series Wide-Field Optical Coherence Tomography (OCT) system for real-time microstructural imaging across various tissues, including breast, kidney, and lung. Presentations addressed the intraoperative evaluation of tissue in head and neck surgery, supporting the device's potential to enhance surgical outcomes. The device offers 10x greater resolution than X-ray and 100x that of MRI, aligning with the company's mission to improve cancer surgery.

Perimeter Medical Imaging AI announced its graduation from a Tier 2 Issuer to a Tier 1 Issuer on the TSX Venture Exchange, effective October 5, 2022. This upgrade reflects the Company’s significant financial resources and sustainable business model, with cash and cash equivalents totaling $44,966,273 as of June 30, 2022. The transition allows for the release of 5,080,959 shares from escrow, better positioning Perimeter for growth in the medical imaging sector.

Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) has successfully placed its Perimeter S-Series OCT system in a major North Texas healthcare network hospital. This marks a significant step in validating their commercial model, highlighting their commitment to enhancing cancer surgery outcomes with advanced imaging technology. The Perimeter S-Series OCT offers real-time, high-resolution tissue visualization, aiming to reduce healthcare costs. CEO Jeremy Sobotta expressed enthusiasm about the system's potential impact on patient care and the interest from top surgeons.

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) reported its second quarter results on August 24, 2022. The company anticipates 10-20 commercial installations for its S-Series OCT device, reflecting increased market opportunities. Operating expenses amounted to $6.3 million, up from $3.1 million a year prior, while the net loss narrowed to $366,296 compared to $3.2 million in Q2 2021. Cash and cash equivalents stood at $44.97 million. The company is progressing in its pivotal clinical trial for the B-Series OCT system, with seven out of eight sites activated.

Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) will announce its second quarter 2022 financial results after U.S. markets close on August 24, 2022. A conference call is scheduled for the same day at 5:00 PM ET, featuring key executives including CEO Jeremy Sobotta and CFO Chris Scott. Participants can join via dial-in or through a live webcast, with playback available for 14 days post-call. The company focuses on enhancing cancer surgery through innovative imaging solutions, including FDA-cleared systems for real-time visualization of excised tissues.